Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE45313 | SANOFI-AVENTIS US | Exendin variant peptides |
Jul, 2020
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9855388 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Apr, 2029
(4 years from now) | |
US8915888 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Jun, 2030
(6 years from now) | |
US9981013 | SANOFI-AVENTIS US | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
Aug, 2030
(6 years from now) | |
US10028910 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
Nov, 2030
(6 years from now) | |
US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(6 years from now) | |
US9308329 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(6 years from now) | |
US8475414 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(6 years from now) | |
US8882721 | SANOFI-AVENTIS US | Drive assembly suitable for use in a drug delivery device and drug delivery device |
Jun, 2031
(7 years from now) | |
US9084853 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Oct, 2031
(7 years from now) | |
US9511193 | SANOFI-AVENTIS US | Assembly and indicator for a drug delivery device |
Jan, 2032
(7 years from now) | |
US9440029 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Jan, 2032
(7 years from now) | |
US9072836 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Mar, 2032
(7 years from now) | |
US9821032 | SANOFI-AVENTIS US | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(8 years from now) | |
US9408893 | SANOFI-AVENTIS US | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
Aug, 2032
(8 years from now) | |
US10201663 | SANOFI-AVENTIS US | Assembly for a drug delivery device |
Mar, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector; Improvement of glycemic control in type 2 diabetes patients by administering a starting dose of 10 mcg fo...
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
USRE45313 | NA | Exendin variant peptides |
Jul, 2025
(1 year, 2 months from now) |
Ingredients: LIXISENATIDE